|

GR1803 injection Clinical Trials

2 actively recruiting trials

▼ -1 trial since May 2026

Pipeline

Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Genrix (Shanghai) Biopharmaceutical Co., Ltd.2

Indications

  • Auto Immune Disease1
  • Systemic Lupus Erthematosus1
  • Lupus1
  • Multiple Myeloma1
  • Cancer1

Other2 trials

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3
A Study of GR1803 in Systemic Lupus Erythematosus
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.